Journal Logo

January 25th, 2003 - Volume 25 - Issue 2
pp: 3-37

What Oncologists Should Know About the Smallpox Vaccine

Klein, Joan

Oncology Times. 25(2):3-4, January 25th, 2003.

As public officials finalize a national smallpox vaccination plan, health care professionals need to be educated about the disease, which has not been a part of medical education for more than 25 years. Neal Halsey, MD, Director of the Johns Hopkins Institute for Vaccine Safety, zeroes in on what's important.

Committee Rejects Expansion of Casodex Use, Recommends Approval for Bexxar

Frieden, Joyce

Oncology Times. 25(2):5-8, January 25th, 2003.

The Oncologic Drugs Advisory Committee voted not to recommend approval for a second and third indication for bicalutamide (Casodex), but did advise approval for tositumomab and iodine I-131 tositumomab (Bexxar) for advanced NHL, although one FDA official expressed concern about how easy the drug would be to administer.

How Patients & Consumers Affect the Development of Cancer Drugs

Fromer, Margot J.

Oncology Times. 25(2):13,14, January 25th, 2003.

ODAC is currently the only FDA advisory committee on which consumer representatives vote. Here's how they are chosen and details on how the process works, including a frank look at the challenges these patients, family members, and advocates face in getting their views heard.





Managing Anemia in Cancer Patients: Guidelines Evolve to Reflect New Choices, New Directions

Henkel, Gretchen

Oncology Times. 25(2):30-32, January 25th, 2003.

As late as the mid-1980s, standard therapy for managing anemia in cancer patients was red blood cell transfusion, whose benefits lasted for only a month or less. Experts interviewed for this article include those on the panel that created the ASCO/ASH clinical guidelines, which concluded that epoetin alfa can be useful for treating anemia in cancer patients whose hemoglobin is 10 g/dL or less. Given the rapidly changing field, however, updates will soon be needed.